Hoth Therapeutics, a biopharmaceutical company, has completed Phase I of its In-Life dose escalation study intended for treating Eczema, it was reported yesterday.
An independent third party conducted the clinical study by monitoring the tolerance and toxicity of its proprietary BioLexa Platform on minipigs.
The study had two phases with the first phase of the study being completed in September of 2019.
Robb Knie, chief executive officer of Hoth Therapeutics, said, 'Management is pleased that our BioLexa Platform continues to demonstrate an impressive safety profile during its testing phase. We believe this therapeutic candidate has the potential to provide significant benefits to people afflicted by Atopic Dermatitis. Going forward, we are focused on expanding our clinical efforts into later stage trials.'
Sobi's Biologics License Application for NASP in uncontrolled gout accepted by FDA
Hydrosome Labs announces promising fermentation breakthrough with ultrafine bubbles
Ionis receives FDA Breakthrough Therapy designation for ION582 in Angelman syndrome
AMO Pharma signs licence agreement with PHRI and Venca Research Inc to advance new study in ARVC
Saol Therapeutics receives US FDA Complete Response Letter for SL1009 (DCA) in PDCD
Amgen and Kyowa Kirin release rocatinlimab study results in atopic dermatitis
Hemogenyx Pharmaceuticals partners with Made Scientific to advance CAR-T therapy
Lilly's Jaypirca delivers breakthrough results in front-line CLL trial